SK2862004A3 - Amlodipine bezylate tablets with improved stability - Google Patents

Amlodipine bezylate tablets with improved stability Download PDF

Info

Publication number: SK2862004A3
Authority: SK; Slovakia
Prior art keywords: tablets; amlodipine; active ingredient; weight; max
Prior art date: 2001-12-17

Application number

SK286-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Pal Fekete

Ignacz Maria Kiralyne

Peter Tompe

Laszlone Gora

Palne Szentgroti

Huszar Magdolna Leventiszne

Palne Thuroczi

Magyar Olga Lonkaine

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-17

Filing date

2002-12-17

Publication date

2004-11-03

2002-12-17 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2004-11-03 Publication of SK2862004A3 publication Critical patent/SK2862004A3/sk

Links

HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 36
229960000528 amlodipine Drugs 0.000 title claims abstract description 25
239000004480 active ingredient Substances 0.000 claims abstract description 42
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 22
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 22
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 22
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 22
239000000314 lubricant Substances 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims abstract description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 6
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 24
229960004005 amlodipine besylate Drugs 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 21
239000007884 disintegrant Substances 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 8
239000008119 colloidal silica Substances 0.000 claims description 5
238000007906 compression Methods 0.000 claims description 5
230000006835 compression Effects 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 abstract description 3
229940075614 colloidal silicon dioxide Drugs 0.000 abstract description 3
230000009965 odorless effect Effects 0.000 description 18
238000011109 contamination Methods 0.000 description 17
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
229920002472 Starch Polymers 0.000 description 10
239000008107 starch Substances 0.000 description 10
229940032147 starch Drugs 0.000 description 10
235000019698 starch Nutrition 0.000 description 10
238000004090 dissolution Methods 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
238000007907 direct compression Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000000126 substance Substances 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000008101 lactose Substances 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
238000003860 storage Methods 0.000 description 5
-1 2 - [(2-Aminoethoxy) methyl] -4- (2-chlorophenyl) -1,4-dihydro-6-methyl-3-ethyl-3,5-pyridinedicarboxylic acid 5-methyl ester Chemical compound 0.000 description 4
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
239000000047 product Substances 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
229920003110 Primojel Polymers 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
239000012738 dissolution medium Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
230000002906 microbiologic effect Effects 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000013112 stability test Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
239000005429 MCC/DCP excipient Substances 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
230000002213 calciumantagonistic effect Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000002706 dry binder Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000003475 lamination Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940036132 norvasc Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK286-2004A 2001-12-17 2002-12-17 Amlodipine bezylate tablets with improved stability SK2862004A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0105345A HU226642B1 (en)	2001-12-17	2001-12-17	Amlodipine bezylate tablets having extended stability and process for producing the same
PCT/HU2002/000145 WO2003051364A1 (en)	2001-12-17	2002-12-17	Amlopidine bezylate tablets with improved stability

Publications (1)

Publication Number	Publication Date
SK2862004A3 true SK2862004A3 (en)	2004-11-03

Family

ID=90000366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK286-2004A SK2862004A3 (en)	2001-12-17	2002-12-17	Amlodipine bezylate tablets with improved stability

Country Status (17)

Country	Link
EP (1)	EP1458384B1 (de)
AT (1)	ATE333877T1 (de)
AU (1)	AU2002353242A1 (de)
BG (1)	BG108807A (de)
CZ (1)	CZ2004791A3 (de)
DE (1)	DE60213464T2 (de)
EA (1)	EA006826B1 (de)
ES (1)	ES2269787T3 (de)
HR (1)	HRP20040582B1 (de)
HU (1)	HU226642B1 (de)
LT (1)	LT5241B (de)
LV (1)	LV13243B (de)
PL (1)	PL370420A1 (de)
RS (1)	RS54304A (de)
SK (1)	SK2862004A3 (de)
UA (1)	UA74968C2 (de)
WO (1)	WO2003051364A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006059217A1 (en) *	2004-12-01	2006-06-08	Ranbaxy Laboratories Limited	Stable solid dosage forms of amlodipine besylate and processes for their preparation
RU2359672C1 (ru) *	2008-02-18	2009-06-27	Зао "Биоком"	Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
JO3239B1 (ar)	2008-09-22	2018-03-08	Novartis Ag	تركيبات جالينية من مركبات عضوية
JP4954961B2 (ja) *	2008-10-06	2012-06-20	大日本住友製薬株式会社	光安定性の向上した組成物
JP5689052B2 (ja) *	2011-12-26	2015-03-25	大日本住友製薬株式会社	光安定性の向上した組成物
BR112014020184B1 (pt)	2012-02-17	2021-11-30	Egis Gyógyszergyár Zrt	Preparação farmacêutica que contém anlodipina e ra-mipril
PL236001B1 (pl)	2012-12-21	2020-11-30	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US10350171B2 (en)	2017-07-06	2019-07-16	Dexcel Ltd.	Celecoxib and amlodipine formulation and method of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8608335D0 (en) *	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
DE19857716A1 (de) *	1998-12-15	2000-06-21	Bayer Ag	Neue feste Formulierung von Metrifonat
WO2003032954A1 (en) *	2001-10-17	2003-04-24	Dr. Reddy's Laboratories Ltd.	Stabilized pharmaceutical formulations containing amlodipine maleate

2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
2002
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/en not_active Ceased
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 EP EP02788262A patent/EP1458384B1/de not_active Expired - Lifetime
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
2004
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown

Also Published As

Publication number	Publication date
LV13243B (en)	2005-05-20
CZ2004791A3 (cs)	2004-10-13
HU226642B1 (en)	2009-05-28
HUP0105345A3 (en)	2007-08-28
LT5241B (lt)	2005-07-25
EA006826B1 (ru)	2006-04-28
HRP20040582B1 (en)	2007-08-31
HUP0105345D0 (en)	2002-02-28
ES2269787T3 (es)	2007-04-01
UA74968C2 (en)	2006-02-15
EA200400801A1 (ru)	2004-12-30
EP1458384A1 (de)	2004-09-22
HRP20040582A2 (en)	2005-02-28
RS54304A (sr)	2006-12-15
DE60213464D1 (de)	2006-09-07
BG108807A (en)	2005-03-31
HUP0105345A2 (hu)	2003-12-29
PL370420A1 (en)	2005-05-30
EP1458384B1 (de)	2006-07-26
ATE333877T1 (de)	2006-08-15
WO2003051364A1 (en)	2003-06-26
DE60213464T2 (de)	2007-03-01
AU2002353242A1 (en)	2003-06-30
LT2004062A (en)	2005-02-25

Legal Events

Date	Code	Title	Description
2010-05-07	FD9A	Suspended procedure due to non-payment of fee

Publication	Publication Date	Title
RU2311903C2 (ru)	2007-12-10	Таблетки тамзулосина
US20090226510A1 (en)	2009-09-10	Pharmaceutical compositions of atorvastatin
US20090196932A1 (en)	2009-08-06	Pharmaceutical compositions of atorvastatin
IL162451A (en)	2009-02-11	5ht4 partial agonist pharmaceutical compositions
SK18062002A3 (sk)	2003-07-01	Pevné orálne farmaceutické kompozície obsahujúce valsartan
KR100760112B1 (ko)	2007-09-18	아토르바스타틴의 제약 조성물
EP1458384B1 (de)	2006-07-26	Amlopidinbezylat-tabletten mit verbesserter stabilität
CA2905423A1 (en)	2014-09-25	Sovaprevir tablets
EP2179725A1 (de)	2010-04-28	Pharmazeutische Zusammensetzung mit Levetiracetan
EP2559431A1 (de)	2013-02-20	Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid
WO2006059217A1 (en)	2006-06-08	Stable solid dosage forms of amlodipine besylate and processes for their preparation
CA2450001A1 (en)	2003-01-03	Stable pharmaceutical compositions containing pravastatin
US20090269409A1 (en)	2009-10-29	Pharmaceutical compositions comprising eszopiclone
RU2674978C2 (ru)	2018-12-14	Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида
US20070281000A1 (en)	2007-12-06	Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
CA2343949A1 (en)	2002-10-12	Benazepril hydrochloride tablet formulations
EP1864677A1 (de)	2007-12-12	Stabile Zubereitung enthaltend eine feuchtigkeitsemphindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.
WO2007142628A1 (en)	2007-12-13	Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
Mohammed	0	Preparation Method and in Vitro Evaluation Method of Rosuvastatin Porous Tablets
AU2005200815A1 (en)	2005-03-17	Solid valsartan pharmaceutical compositions